Cancer Targeted Therapy

mPEG2000-DMPE is a pegylated lipid with a methyl group at the opposite end of the PEG chain, and can be used for the preparation of lipid nanoparticles or liposomes for targeted drug delivery applications. mPEG2000-DMPE is applicable for siRNA-related application studies targeting macrophages and dendritic cells.

PROTAC Her3 Degrader-2 is a Her3 PROTAC degrader with an IC₅₀ < 10 nM. PROTAC Her3 Degrader-2 recruits Her3 to E3 ubiquitin ligase to achieve selective degradation. PROTAC Her3 Degrader-2 can be used in the research of breast cancer, lung cancer, head and neck cancer, and prostate cancer.

N3-PEG8-CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. N3-PEG8-CH2COOH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

DPP-21 is an inhibitor of tubulin polymerization (IC₅₀: 2.4 μM). DPP-21 shows anti-proliferative activity against cancer cell lines, with IC₅₀s of 0.38 nM (HCT116), 11.69 nM (B16), 5.37 nM (HeLa), 9.53 nM (MCF7), 8.94 nM (H23) and 9.37 nM (HepG2) respectively. DPP-21 arrests the cell cycle in the G2/M phase of mitosis, subsequently inducing tumor cell apoptosis (decreases Bcl-2 but upregulates the pro-apoptotic protein Bax).

UR-MB108 is a selective ABCG2 inhibitor with an IC₅₀ value of 79 nM. UR-MB108 acts as a potent inhibitor of ABCG2 transport and ATPase activity. UR-MB108 can be used in cancer-related research.

EGFR-IN-156 (Compound 7f) is an EGFR inhibitor that also has inhibitory activity against mutations EGFRL858R and EGFRT790M (IC₅₀ values are 0.186, 0.131, and 0.107 μM, respectively). EGFR-IN-156 has significant anticancer activity against human cancer cell lines HepG-29 (liver cancer), MCF-7 (breast cancer), and HCT-116 (colon cancer) (IC₅₀ values are 1.67, 5.32, and 6.56 μM, respectively). EGFR-IN-156 inhibits cancer cell proliferation by inducing cell cycle arrest at the G/G1 phase and triggering apoptosis. EGFR-IN-156 shows promise in EGFR-related cancers.

Pixofisiran sodium scrambled negative control is the sequence scrambled negative control of Pixofisiran sodium.

SOS1/KRAS-IN-1(Compound 2) is a SOS1/KRAS inhibitor, which can be used in the research of SOS1/KRAS-mediated diseases.

PROTAC SMARCA2 degrader-36 (Compound 26) is a selective and potent SMARCA2 PROTAC degrader with a DC₅₀ of 51 nM. PROTAC SMARCA2 degrader-36 promotes ubiquitination and degradation of SMARCA2. PROTAC SMARCA2 degrader-36 exhibits anticancer activity against non-small cell lung cancer. PROTAC SMARCA2 degrader-36 can be used in studies related to SMARCA4-deficient cancers.

DMG-PEG2000-GE11 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and GE11 peptide (YHWYGYTPQNVI) (HY-P10128) as the terminal targeting/functional ligand. DMG-PEG2000-GE11 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against EGFR (HER1) on the surface of various epithelial tumor cells (lung cancer, breast cancer, colorectal cancer, head and neck cancer).

AKT-IN-20 is an AKT inhibitor, and can be used for research of cancer

RIP1 kinase inhibitor 9 (compound SY-1) is a selective RIP kinase inhibitor. RIP1 kinase inhibitor 9 effectively suppresses the central inflammatory response induced by epilepsy. RIP1 kinase inhibitor 9 inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis in HT-29 cells with an EC₅₀ of 7.04 nM.

BAT-6021 is a human monoclonal antibody (mAb) targeting TIGIT. BAT-6021 can be used in Solid tumours research.

hsa-miR-1255b-2-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-412-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-701-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

rno-miR-3547 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

Antimetastatic agent-1 (Compound A-23) is a MET inhibitor. Antimetastatic agent-1 can inhibit cancer metastasis.

p38α inhibitor 4 (compound 10) is a selective and allosteric p38α inhibitor with an IC₅₀ value of 1.2 μM. p38α inhibitor 4 exhibits no activity against p38β, p38γ, and p38δ.

WEE1/PKMYT1-IN-2 is the axial chiral P configuration of WEE1/PKMYT1-IN-1 (HY-169946). WEE1/PKMYT1-IN-1 is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity.